Drug repositioning: bringing new life to shelved assets and existing drugs
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Hoboken, N.J.
Wiley
©2012
|
| Schlagworte: | |
| Online-Zugang: | FRO01 UBG01 Volltext |
| Beschreibung: | Includes bibliographical references and index BThe how's and why's of successful drug repositioning /b/ Drug repositioning, also known as drug reprofiling or repurposing, has become an increasingly important part of the drug development process. This book examines the business, technical, scientific, and operational challenges and opportunities that drug repositioning offers. Readers will learn how to perform the latest experimental and computational methods that support drug repositioning, and detailed case studies throughout the book demonstrate how these methods fit within the context of a comprehensive drug repositioning strategy./ iDrug Repositioning/i is divided into three parts:/ ulli bPart 1, Drug Repositioning: Business Case, Strategies, and Operational Considerations, /b examines the medical and commercial drivers underpinning the quest to reposition existing drugs, guiding readers through the key strategic, technical, operational, and regulatory decisions needed for successful drug repositioning programs./ /lili bPart 2, Application of Technology Platforms to Uncover New Indications and Repurpose Existing Drugs, /b sets forth computational-based strategies, tools, and databases that have been designed for repositioning studies, screening approaches, including combinations of existing drugs, and a look at the development of chemically modified analogs of approved agents./ /lili bPart 3, Academic and Non-Profit Initiatives & the Role of Alliances in the Drug Repositioning Industry/b, explores current investigations for repositioning drugs to treat rare and neglected diseases, which are frequently overlooked by for-profit pharmaceutical companies due to their lack of commercial return./ /li/ul The book's appendix provides valuable resources for drug repositioning researchers, including information on drug repositioning and reformulation companies, databases, government resources and organizations, regulatory agencies, and drug repositioning initiatives from academia and non-profits./ With this book as their guide, students and pharmaceutical researchers can learn how to use drug repositioning techniques to extend the lifespan and applications of existing drugs as well as maximize the return on investment in drug research and development |
| Beschreibung: | 1 Online-Ressource (xx, 477 pages) |
| ISBN: | 9781118274408 1118274407 9781118274392 1118274393 9781118274378 1118274377 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043394928 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 160222s2012 |||| o||u| ||||||eng d | ||
| 020 | |a 9781118274408 |c electronic bk. |9 978-1-118-27440-8 | ||
| 020 | |a 1118274407 |c electronic bk. |9 1-118-27440-7 | ||
| 020 | |a 9781118274392 |c electronic bk. |9 978-1-118-27439-2 | ||
| 020 | |a 1118274393 |c electronic bk. |9 1-118-27439-3 | ||
| 020 | |a 9781118274378 |c electronic bk. |9 978-1-118-27437-8 | ||
| 020 | |a 1118274377 |c electronic bk. |9 1-118-27437-7 | ||
| 024 | 7 | |a 10.1002/9781118274408 |2 doi | |
| 035 | |a (ZDB-35-WIC)ocn802068199 | ||
| 035 | |a (OCoLC)802068199 | ||
| 035 | |a (DE-599)BVBBV043394928 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-861 | ||
| 082 | 0 | |a 338.4/76151 |2 23 | |
| 245 | 1 | 0 | |a Drug repositioning |b bringing new life to shelved assets and existing drugs |c edited by Michael J. Barratt, Donald E. Frail |
| 264 | 1 | |a Hoboken, N.J. |b Wiley |c ©2012 | |
| 300 | |a 1 Online-Ressource (xx, 477 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 500 | |a BThe how's and why's of successful drug repositioning /b/ Drug repositioning, also known as drug reprofiling or repurposing, has become an increasingly important part of the drug development process. This book examines the business, technical, scientific, and operational challenges and opportunities that drug repositioning offers. | ||
| 500 | |a Readers will learn how to perform the latest experimental and computational methods that support drug repositioning, and detailed case studies throughout the book demonstrate how these methods fit within the context of a comprehensive drug repositioning strategy./ iDrug Repositioning/i is divided into three parts:/ ulli bPart 1, Drug Repositioning: Business Case, Strategies, and Operational Considerations, /b examines the medical and commercial drivers underpinning the quest to reposition existing drugs, guiding readers through the key strategic, technical, operational, and regulatory decisions needed for successful drug repositioning programs./ /lili bPart 2, Application of Technology Platforms to Uncover New Indications and Repurpose Existing Drugs, /b sets forth computational-based strategies, tools, and databases that have been designed for repositioning studies, screening approaches, including combinations of existing drugs, | ||
| 500 | |a and a look at the development of chemically modified analogs of approved agents./ /lili bPart 3, Academic and Non-Profit Initiatives & the Role of Alliances in the Drug Repositioning Industry/b, explores current investigations for repositioning drugs to treat rare and neglected diseases, which are frequently overlooked by for-profit pharmaceutical companies due to their lack of commercial return./ /li/ul The book's appendix provides valuable resources for drug repositioning researchers, including information on drug repositioning and reformulation companies, databases, government resources and organizations, regulatory agencies, and drug repositioning initiatives from academia and non-profits./ With this book as their guide, students and pharmaceutical researchers can learn how to use drug repositioning techniques to extend the lifespan and applications of existing drugs as well as maximize the return on investment in drug research and development | ||
| 650 | 4 | |a Drug Repositioning | |
| 650 | 4 | |a Computational Biology / methods | |
| 650 | 4 | |a Drug Industry / economics | |
| 650 | 4 | |a Pharmaceutical Preparations / economics | |
| 650 | 4 | |a Medical | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 7 | |a Drug development |2 fast | |
| 650 | 7 | |a Pharmaceutical industry |2 fast | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Drug development | |
| 650 | 4 | |a Pharmaceutical industry | |
| 653 | |a Electronic books | ||
| 700 | 1 | |a Barratt, Michael J. |e Sonstige |4 oth | |
| 700 | 1 | |a Frail, Donald |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 978-0-470-87827-9 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 0-470-87827-4 |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/book/10.1002/9781118274408 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-35-WIC | ||
| 940 | 1 | |q UBG_PDA_WIC | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028813512 | ||
| 966 | e | |u https://onlinelibrary.wiley.com/doi/book/10.1002/9781118274408 |l FRO01 |p ZDB-35-WIC |q FRO_PDA_WIC |x Verlag |3 Volltext | |
| 966 | e | |u https://onlinelibrary.wiley.com/doi/book/10.1002/9781118274408 |l UBG01 |p ZDB-35-WIC |q UBG_PDA_WIC |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175974209683456 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV043394928 |
| collection | ZDB-35-WIC |
| ctrlnum | (ZDB-35-WIC)ocn802068199 (OCoLC)802068199 (DE-599)BVBBV043394928 |
| dewey-full | 338.4/76151 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.4/76151 |
| dewey-search | 338.4/76151 |
| dewey-sort | 3338.4 576151 |
| dewey-tens | 330 - Economics |
| discipline | Wirtschaftswissenschaften |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04702nmm a2200637zc 4500</leader><controlfield tag="001">BV043394928</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">160222s2012 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781118274408</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-1-118-27440-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1118274407</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">1-118-27440-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781118274392</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-1-118-27439-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1118274393</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">1-118-27439-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781118274378</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-1-118-27437-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1118274377</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">1-118-27437-7</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1002/9781118274408</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-35-WIC)ocn802068199</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)802068199</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043394928</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-861</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">338.4/76151</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug repositioning</subfield><subfield code="b">bringing new life to shelved assets and existing drugs</subfield><subfield code="c">edited by Michael J. Barratt, Donald E. Frail</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hoboken, N.J.</subfield><subfield code="b">Wiley</subfield><subfield code="c">©2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (xx, 477 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">BThe how's and why's of successful drug repositioning /b/ Drug repositioning, also known as drug reprofiling or repurposing, has become an increasingly important part of the drug development process. This book examines the business, technical, scientific, and operational challenges and opportunities that drug repositioning offers. </subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Readers will learn how to perform the latest experimental and computational methods that support drug repositioning, and detailed case studies throughout the book demonstrate how these methods fit within the context of a comprehensive drug repositioning strategy./ iDrug Repositioning/i is divided into three parts:/ ulli bPart 1, Drug Repositioning: Business Case, Strategies, and Operational Considerations, /b examines the medical and commercial drivers underpinning the quest to reposition existing drugs, guiding readers through the key strategic, technical, operational, and regulatory decisions needed for successful drug repositioning programs./ /lili bPart 2, Application of Technology Platforms to Uncover New Indications and Repurpose Existing Drugs, /b sets forth computational-based strategies, tools, and databases that have been designed for repositioning studies, screening approaches, including combinations of existing drugs, </subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">and a look at the development of chemically modified analogs of approved agents./ /lili bPart 3, Academic and Non-Profit Initiatives & the Role of Alliances in the Drug Repositioning Industry/b, explores current investigations for repositioning drugs to treat rare and neglected diseases, which are frequently overlooked by for-profit pharmaceutical companies due to their lack of commercial return./ /li/ul The book's appendix provides valuable resources for drug repositioning researchers, including information on drug repositioning and reformulation companies, databases, government resources and organizations, regulatory agencies, and drug repositioning initiatives from academia and non-profits./ With this book as their guide, students and pharmaceutical researchers can learn how to use drug repositioning techniques to extend the lifespan and applications of existing drugs as well as maximize the return on investment in drug research and development</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Repositioning</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Computational Biology / methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry / economics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical Preparations / economics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medical</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug development</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical industry</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Electronic books</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barratt, Michael J.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Frail, Donald</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">978-0-470-87827-9</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">0-470-87827-4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/9781118274408</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-35-WIC</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">UBG_PDA_WIC</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028813512</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/9781118274408</subfield><subfield code="l">FRO01</subfield><subfield code="p">ZDB-35-WIC</subfield><subfield code="q">FRO_PDA_WIC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/9781118274408</subfield><subfield code="l">UBG01</subfield><subfield code="p">ZDB-35-WIC</subfield><subfield code="q">UBG_PDA_WIC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043394928 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:24:48Z |
| institution | BVB |
| isbn | 9781118274408 1118274407 9781118274392 1118274393 9781118274378 1118274377 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028813512 |
| oclc_num | 802068199 |
| open_access_boolean | |
| owner | DE-861 |
| owner_facet | DE-861 |
| physical | 1 Online-Ressource (xx, 477 pages) |
| psigel | ZDB-35-WIC UBG_PDA_WIC ZDB-35-WIC FRO_PDA_WIC ZDB-35-WIC UBG_PDA_WIC |
| publishDate | 2012 |
| publishDateSearch | 2012 |
| publishDateSort | 2012 |
| publisher | Wiley |
| record_format | marc |
| spelling | Drug repositioning bringing new life to shelved assets and existing drugs edited by Michael J. Barratt, Donald E. Frail Hoboken, N.J. Wiley ©2012 1 Online-Ressource (xx, 477 pages) txt rdacontent c rdamedia cr rdacarrier Includes bibliographical references and index BThe how's and why's of successful drug repositioning /b/ Drug repositioning, also known as drug reprofiling or repurposing, has become an increasingly important part of the drug development process. This book examines the business, technical, scientific, and operational challenges and opportunities that drug repositioning offers. Readers will learn how to perform the latest experimental and computational methods that support drug repositioning, and detailed case studies throughout the book demonstrate how these methods fit within the context of a comprehensive drug repositioning strategy./ iDrug Repositioning/i is divided into three parts:/ ulli bPart 1, Drug Repositioning: Business Case, Strategies, and Operational Considerations, /b examines the medical and commercial drivers underpinning the quest to reposition existing drugs, guiding readers through the key strategic, technical, operational, and regulatory decisions needed for successful drug repositioning programs./ /lili bPart 2, Application of Technology Platforms to Uncover New Indications and Repurpose Existing Drugs, /b sets forth computational-based strategies, tools, and databases that have been designed for repositioning studies, screening approaches, including combinations of existing drugs, and a look at the development of chemically modified analogs of approved agents./ /lili bPart 3, Academic and Non-Profit Initiatives & the Role of Alliances in the Drug Repositioning Industry/b, explores current investigations for repositioning drugs to treat rare and neglected diseases, which are frequently overlooked by for-profit pharmaceutical companies due to their lack of commercial return./ /li/ul The book's appendix provides valuable resources for drug repositioning researchers, including information on drug repositioning and reformulation companies, databases, government resources and organizations, regulatory agencies, and drug repositioning initiatives from academia and non-profits./ With this book as their guide, students and pharmaceutical researchers can learn how to use drug repositioning techniques to extend the lifespan and applications of existing drugs as well as maximize the return on investment in drug research and development Drug Repositioning Computational Biology / methods Drug Industry / economics Pharmaceutical Preparations / economics Medical MEDICAL / Pharmacology bisacsh Drug development fast Pharmaceutical industry fast Medizin Drug development Pharmaceutical industry Electronic books Barratt, Michael J. Sonstige oth Frail, Donald Sonstige oth Erscheint auch als Druck-Ausgabe, Hardcover 978-0-470-87827-9 Erscheint auch als Druck-Ausgabe, Hardcover 0-470-87827-4 https://onlinelibrary.wiley.com/doi/book/10.1002/9781118274408 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Drug repositioning bringing new life to shelved assets and existing drugs Drug Repositioning Computational Biology / methods Drug Industry / economics Pharmaceutical Preparations / economics Medical MEDICAL / Pharmacology bisacsh Drug development fast Pharmaceutical industry fast Medizin Drug development Pharmaceutical industry |
| title | Drug repositioning bringing new life to shelved assets and existing drugs |
| title_auth | Drug repositioning bringing new life to shelved assets and existing drugs |
| title_exact_search | Drug repositioning bringing new life to shelved assets and existing drugs |
| title_full | Drug repositioning bringing new life to shelved assets and existing drugs edited by Michael J. Barratt, Donald E. Frail |
| title_fullStr | Drug repositioning bringing new life to shelved assets and existing drugs edited by Michael J. Barratt, Donald E. Frail |
| title_full_unstemmed | Drug repositioning bringing new life to shelved assets and existing drugs edited by Michael J. Barratt, Donald E. Frail |
| title_short | Drug repositioning |
| title_sort | drug repositioning bringing new life to shelved assets and existing drugs |
| title_sub | bringing new life to shelved assets and existing drugs |
| topic | Drug Repositioning Computational Biology / methods Drug Industry / economics Pharmaceutical Preparations / economics Medical MEDICAL / Pharmacology bisacsh Drug development fast Pharmaceutical industry fast Medizin Drug development Pharmaceutical industry |
| topic_facet | Drug Repositioning Computational Biology / methods Drug Industry / economics Pharmaceutical Preparations / economics Medical MEDICAL / Pharmacology Drug development Pharmaceutical industry Medizin |
| url | https://onlinelibrary.wiley.com/doi/book/10.1002/9781118274408 |
| work_keys_str_mv | AT barrattmichaelj drugrepositioningbringingnewlifetoshelvedassetsandexistingdrugs AT fraildonald drugrepositioningbringingnewlifetoshelvedassetsandexistingdrugs |